

From: Blake, Nikki <Nikki.Blake@carefirst.com>
Sent: Friday, October 6, 2023 2:36 PM
To: Senkewicz, MaryBeth E. (DCHBX-Contractor) <marybeth.senkewicz@dc.gov>
Cc: Beard, Andre (DCHBX) <andre.beard1@dc.gov>
Subject: RE: Rx List

CAUTION: This email originated from outside of the DC Government. Do not click on links or open attachments unless you recognize the sender and know that the content is safe. If you believe that this email is suspicious, please forward to phishing@dc.gov for additional analysis by OCTO Security Operations Center (SOC).

Hi MaryBeth,

I had one of our pharmacists review. Their response is below.

It looks like for each tab, column B is showing generic name, and column D is showing brand name. I'm assuming that when these match, it is truly the generic product. I'm seeing a few rows throughout where they don't match, and the products trade/brand name is listed instead. I'm presuming these are actually brand versions of these generically available drugs.

I've listed the worksheets, brand name, and row numbers where I'm seeing this.

ACE Inhibitors:

Zestril: 127, 217, 220, 259, 275

Lotrel: 462-465

Qbrelis: 475

Zestoretic: 482-484

Statins:

Lipitor: 286, 287, 291, 292